NVNO (envveno.com) צמיחת רווח למניה השנה

The high market capacity potential of vascular centers drives EPS growth compared to the same period last year, where the current status is 0.00. enVVeno Medical (NVNO) bases its success on patents for unique venous prostheses designed for long-term treatment. The production model relies on sourcing components from vendors while maintaining strict internal sterility and quality control.
פילוחי מדדים פיננסיים ומדדי שוק עבור enVVeno (NVNO)

enVVeno Medical focuses on creating an innovative bioprosthesis for the treatment of venous insufficiency. This indicator captures the percentage deviation of net earnings per share relative to the same period last year. Analyzing this trend allows for the identification of cost control efficiency amidst expensive clinical trials. A positive trend confirms the viability of the business model and growth in capitalization. By assessing the volatility of earnings per share compared to last year, an investor determines the company's resilience to inflationary pressure.